Monocenter, double blinded, prospective, randomized placebo controlled study investigating prevention of major adverse cardiac events (MACEs) within 6 months by systemic treatment with everolimus after coronary intervention with bare metal stents in patients with significant coronary artery disease
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Adverse reactions; First in man
- 16 Feb 2007 New trial record.